Ensysce Biosciences, Inc. (ENSC) stock
ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.38−0.03 (-6.28%)
Close on Nov 17, 2026Market cap $7.47MP/E –Yield –
Ensysce Biosciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Ensysce Biosciences's total debt was $140.15K at Dec 31, 2022. For fiscal 2022 it was $140.15K, down 96.8% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $140.15K | -96.8% |
| FY2021 | Dec 31, 2021 | $4.44M | +684.2% |
| FY2020 | Dec 31, 2020 | $566.29K | +0.0% |
| FY2019 | Dec 31, 2019 | $566.27K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | $140.15K | -96.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.39M | -34.4% |
| Q2 FY2022 | Jun 30, 2022 | $137.32K | -75.8% |
| Q1 FY2022 | Mar 31, 2022 | $1.59M | +180.2% |
| Q4 FY2021 | Dec 31, 2021 | $4.44M | +684.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.11M | +273.4% |
| Q4 FY2020 | Dec 31, 2020 | $566.29K | +0.0% |
| Q3 FY2020 | Sep 30, 2020 | $566.27K | – |
| Q2 FY2020 | Jun 30, 2020 | $566.27K | – |
| Q1 FY2020 | Mar 31, 2020 | $566.27K | – |
| Q4 FY2019 | Dec 31, 2019 | $566.27K | – |
See a number that looks wrong?